FDA REFORM ACT'S EDUCATION AND RESEARCH CENTERS HAVE WIDE MANDATE, GIVING AGENCY LATITUDE IN RESEARCH TOPICS; LAW LOOSENS FDA'S OFF-LABEL DATA POLICY
This article was originally published in The Gray Sheet
Executive Summary
The broad mandate of the centers for education and research on therapeutics established by Sec. 409 of the FDA Modernization Act (S 830), which was signed into law Nov. 21, and the modest appropriations level authorized in the bill for the new centers suggests that FDA will have considerable discretion in deciding which research projects the centers choose to pursue.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.